Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Ohshimo, N. Ishikawa, Y. Horimasu, K. Fujitaka, Y. Haruta, H. Murai, N. Hirohashi, N. Hattori, K. Tanigawa, N. Kohno, F. Bonella, J. Guzman, U. Costabel (Hiroshima, Japan; Essen, Bochum, Germany). MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis. Eur Respir J 2013; 42: Suppl. 57, 2351

Member's Comments

No comment yet.

Related content which might interest you: Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016 Difference in the dynamic state between SP-A and SP-D in the IPF lung Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Serum IGFBP2 as a marker of idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Elevation of serum napsin A in interstitial lung diseases in comparison with KL-6 and surfactant protein-D Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Circulating monocytes from interstitial lung disease patients show an activated phenotype Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)? Source: International Congress 2015 – IIPs: orphan Year: 2015 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 IGFBP-2 a new interesting target in IPF Source: International Congress 2016 – ILD pathogenesis Year: 2016 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Seasonal variation of serum KL-6 levels in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 1 Year: 2014 Biomarkers in pulmonary hypertension associated to interstitial lung disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency Source: Eur Respir J 2016; 48: 1510-1514 Year: 2016 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 KL-6/MUC1 in interstitial pneumonia Source: Annual Congress 2005 - Lung-specific serum markers for interstitial lung diseases Year: 2005